Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 901–1,000 of 1,676
Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
Dunbar, R. L., & Goel, H. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0563-8 · Cited by 12
Širc, J., Hrib, J., Vetrík, M., Hobzová, R., Žák, A., Staňková, B., Slanař, O., Hromádka, R., Šandriková, V., & Michálek, J. (2015) · Physiological Research · doi:10.33549/physiolres.933142 · Cited by 11
HDL as a Causal Factor in Atherosclerosis: Insights from Human Genetics
Brunham, L. R. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0623-0 · Cited by 12
Dong, G.-X., Li, W., Wang, R.-Z., Zou, W., Zhong, Z. A., & Li, B. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000500 · Cited by 11
Generoso, G., Benseñor, I. M., Santos, I. S., Santos, R. D., Goulart, A. C., Jones, S. R., Kulkarni, K. R., Blaha, M. J., Toth, P. P., Lotufo, P. A., et al. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118788080 · Cited by 11
Jiang, Y., Jin, M., Chen, J., Yan, J., Liu, P., Yao, M., Cai, W., & Pi, R. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172871 · Cited by 11
The role of intracoronary imaging in translational research
Montarello, N. J., Nelson, A. J., Verjans, J. W. H., Nicholls, S. J., & Psaltis, P. J. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-1 · Cited by 14
Effects of Eicosapentaenoic Acid on Arterial Calcification
Saito, Y., Nakamura, K., & Ito, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155455 · Cited by 12
Janovsky, C. C. P. S., Generoso, G., Goulart, A. C., Santos, R. D., Blaha, M. J., Jones, S. R., Toth, P. P., Lotufo, P. A., Bittencourt, M. S., & Benseñor, I. M. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.021 · Cited by 11
The current landscape of lipoprotein(a) in calcific aortic valvular disease
Hsieh, G., Rizk, T., Berman, A. N., Biery, D. W., & Blankstein, R. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000901 · Cited by 11
“Despite studies showing favorable reduction in Lp(a) with niacin treatment, niacin is not included in current guidelines due to the lack of clinical benefit in patients with atherosclerotic cardiovascular disease (ASCVD) and increased risk of serious adverse events [39].”
BackgroundNiacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients
Shin, S., & Lee, S. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s71559 · Cited by 11
The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology
Pitts, R., & Eckel, R. H. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.2.65 · Cited by 12
Statins and the cholesterol mortality paradox
Nunes, J. P. L. (2016) · Scottish Medical Journal · doi:10.1177/0036933016681913 · Cited by 15
Biologic bases of residual risk of cardiovascular events: A flawed concept
Shapiro, M. D., & Fazio, S. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318798060 · Cited by 12
Cholesterol: Can’t Live With It, Can’t Live Without It
Pownall, H. J., & Gotto, A. M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-9 · Cited by 11
Ganda, O. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000694 · Cited by 12
Radical Thinking: Scientific Rigor and Pragmatism
Evans, S. R. (2022) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2022.2026460 · Cited by 11
“Kaplan–Meier plots of the first major vascular event during the 4 years of follow-up in the HPS2-THRIVE trial (reproduced with permission from Landray et al. 2014).”
BackgroundApproach to the Patient With Moderate Hypertriglyceridemia
Subramanian, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac085 · Cited by 13
Lp(a) - an overlooked risk factor
Laffin, L. J., & Nissen, S. E. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.003 · Cited by 12
HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation
Παπαγεωργίου, Ν., Zacharia, E. M., Androulakis, E. S., Briasoulis, Α., Charakida, M., & Tousoulis, D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1152264 · Cited by 14
Management of Familial Hypercholesterolemia in Hong Kong
Hu, M., Hooper, A. J., BOCKXMEER, F. M. V., Watts, G. F., Chan, J. C. N., & Tomlinson, B. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34314 · Cited by 11
Klinische Bedeutung des HDL-Cholesterins
März, W., Kleber, M. E., Scharnagl, H., Speer, T., Zewinger, S., Ritsch, A., Parhofer, K. G., von Eckardstein, A., Landmesser, U., & Laufs, U. (2016) · Herz · doi:10.1007/s00059-016-4499-0 · Cited by 11
Chronic kidney disease and dyslipidaemia
Pascual, V., Serrano, A., Pedro‐Botet, J., Ascaso, J. F., Barrios, V., Millán, J., Pintó, X., & Cases, A. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2016.04.001 · Cited by 13
Dyslipidemia in Chronic Kidney Disease
Streja, E., & Streja, D. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch34 · Cited by 12
HDL metabolism and function in diabetes mellitus
Cochran, B. J., King, T. W., Chemello, K., Thomas, S. R., & Rye, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01176-y · Cited by 18
Association of major blood lipids with post‐stroke dementia: A community‐based cohort study
Yang, Z., Edwards, D., Burgess, S., Brayne, C., & Mant, J. (2021) · European Journal of Neurology · doi:10.1111/ene.15219 · Cited by 10
HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications
Stoicescu, C. I., Văcărescu, C., & Cozma, D. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144945 · Cited by 17
“Measurement of apoB and non-HDL cholesterol can further refine cardiovascular risk stratification and guide therapeutic decision-making [38,46,53,54,56,57].”
Singh, S. A., Miyosawa, K., & Aikawa, M. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1078731 · Cited by 10
“When compared to LDL-C lowering therapies, HDL-C raising therapies have been relatively unsuccessful [25,40].”
BackgroundHu, M., Yang, Y., Masuda, D., Yamashita, S., & Tomlinson, B. (2015) · Disease Markers · doi:10.1155/2015/154014 · Cited by 10
“However, two recent large outcome studies have shown that the extendedrelease (ER) niacin or the combination of extended-release (ER) niacin and laropiprant (a prostaglandin D2 receptor antagonist developed to reduce niacin-induced flushing) did not significantly further reduce the risk of the cardiovascular event end…”
BackgroundPage, M. M., Hooper, A. J., & Burnett, J. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1129402 · Cited by 12
“However, two large, placebo-controlled outcomes studies have failed to prove any cardiovascular benefit attributable to niacin therapy.[21,22] Key to the protective role of HDL in atherosclerosis is its function, rather than just its particle or cholesterol concentration, with cholesterol efflux capacity, an index”
BackgroundStein, E. A. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000242 · Cited by 10
Kelly, M. S., Beavers, C. J., Bucheit, J. D., Sisson, E. M., & Dixon, D. L. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.05.014 · Cited by 11
Naranjo, M. C., Millán-Linares, M. C., & la Paz, S. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811907-5.00008-7 · Cited by 11
HDL-C, longitudinal change and risk of mortality in a Chinese cohort study
Yang, Z., Wu, M., Lu, J., Zhu, Y., Li, D., Yu, Z., Shen, P., Tang, M., Jin, M., Lin, H., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.06.004 · Cited by 10
HDL as Bidirectional Lipid Vectors: Time for New Paradigms
Luna‐Luna, M., Niesor, E. J., & Pérez-Méndez, O. A. (2022) · Biomedicines · doi:10.3390/biomedicines10051180 · Cited by 11
Turgeon, R. D., Anderson, T. J., Grégoire, J. C., & Pearson, G. J. (2014) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163514561256 · Cited by 10
Bays, H. E., Patel, M. D., Mavros, P., Ramey, D. R., Tomassini, J. E., Tershakovec, A. M., & Baxter, C. A. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.04.121 · Cited by 10
Chen, D., Huang, X., Zhou, H., Luo, H., Wang, P., Chang, Y., He, X., Ni, S., Shen, Q., Cao, G., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.012 · Cited by 11
White, C. M. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418769040 · Cited by 10
Wang, X., Liu, X., Xie, Z., Tian, J., Huang, X., Zhang, R., Chen, S., Hou, J., & Yu, B. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.12.002 · Cited by 13
Androulakis, E. S., Zacharia, E. M., Παπαγεωργίου, Ν., Lioudaki, E., Bertsias, D., Charakida, M., Siasos, G., & Tousoulis, D. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170209145622 · Cited by 11
Bandaru, M. K., Emmanouilidou, A., Ranefall, P., von der Heyde, B., Mazzaferro, E., Klingström, T., Masiero, M. M., Dethlefsen, O., Ledin, J., Larsson, A. O., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/502674 · Cited by 11
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 15
Amigó, N., Torné, P., Nordestgaard, L. T., Barbagallo, F. D. G., Merino, C., Magni, P., González-Lleó, A. M., Andreychuk, N., Catapano, A. L., Masana, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178284 · Cited by 10
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 14
“73,74 Paradoxically, in a recent prospective study, individuals with HDL-C levels greater than 80 mg/dL had a 96% higher risk of all-cause mortality and a 71% higher risk of CV mortality after adjustment for covariates, compared with those with HDL-C levels in the range of 40–60 mg/dL. 75 On the…”
Lipoprotein(a)-lowering therapies: a promising future
Zhang, J., Návar, A. M., & Tokgözoğlu, L. S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag092 · Cited by 14
Proteomic Determinants of Variation in Cholesterol Efflux: Observations from the Dallas Heart Study
Gangwar, A., Deodhar, S., Saldanha, S., Melander, O., Abbasi, F., Pearce, R. W., Collier, T. S., McPhaul, M. J., Furtado, J. D., Sacks, F. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115526 · Cited by 10
“These reports, followed by the well-publicized failure of pharmaceutical interventions to improve ASCVD outcomes, despite successfully raising HDL-C in individuals [8–12], revealed the major flaws in reliance of HDL-C as a reflection of HDL functionality.”
BackgroundSong, S., Lee, C. J., Oh, J., Park, S., Kang, S., & Lee, S. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.1.58 · Cited by 9
Garg, P. K., Jorgensen, N. W., McClelland, R. L., Allison, M., Stein, J. H., Yvan‐Charvet, L., Tall, A. R., & Shea, S. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.007 · Cited by 10
Suter, P. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-805378-2.00017-6 · Cited by 14
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Dubrall, D., Pflock, R., Kosinska, J., Schmid, M. C., Bleich, M., Himmerkus, N., Offermanns, S., Schwaninger, M., & Sachs, B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14787 · Cited by 9
“In two recent clinical studies, significantly higher infection rates were observed for nicotinic acid alone and in combination with laropiprant than for placebo.(36,37) However, this had not been reported in previous studies and is considered controversial.”
ResultHigh Density Lipoproteins: Is There a Comeback as a Therapeutic Target?
von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 13
Naito, R., Daida, H., Masuda, D., Harada‐Shiba, M., Arai, H., Bujo, H., Ishibashi, S., Koga, N., Oikawa, S., & Yamashita, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63019 · Cited by 10
Masana, L., & Plana, N. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.02.004 · Cited by 10
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 10
Lipid Management in Diabetes with a Focus on Emerging Therapies
Hoe, E., & Hegele, R. A. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.012 · Cited by 10
Kent, S., Haynes, R., Hopewell, J. C., Parish, S., Gray, A. M., Landray, M., Collins, R., Armitage, J., & Mihaylova, B. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002592 · Cited by 10
Gupta, S. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83719 · Cited by 11
PCSK9 inhibitors for hypercholesterolaemia
McGettigan, P., & Ferner, R. E. (2017) · BMJ · doi:10.1136/bmj.j188 · Cited by 9
Samadi, S., Abolbashari, S., Meshkat, Z., Mohammadpour, A. H., Kelesidis, T., Gholoobi, A., Mehramiz, M., Tabadkani, M., Sadabadi, F., Dalirfardouei, R., et al. (2019) · BioFactors · doi:10.1002/biof.1489 · Cited by 9
“Niacin and the CETP inhibitors that have been used to increase HDL-C concentrations have no significant impact on CVD outcomes [13].”
BackgroundYousufuddin, M., Zhu, Y., Al-Ward, R., Peters, J., Doyle, T., Jensen, K. L., Wang, Z., & Murad, M. H. (2020) · Open Heart · doi:10.1136/openhrt-2019-001163 · Cited by 12
Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020
Mosca, L. J., Návar, A. M., & WENGER, N. K. (2020) · Journal of Women s Health · doi:10.1089/jwh.2019.8189 · Cited by 10
Supplements for Lipid Lowering: What Does the Evidence Show?
Mirzai, S., & Laffin, L. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01903-9 · Cited by 11
The Effects of Statins on Infections after Stroke or Transient Ischemic Attack: A Meta-Analysis
Lin, S.-P., Long, Y., & Chen, X.-H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130071 · Cited by 9
Mitchel, Y., Bays, H. E., Brinton, E. A., Triscari, J. M., Chen, E., Maccubbin, D., MacLean, A. A., Gibson, K., Ruck, R. A., Johnson‐Levonas, A. O., et al. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s70907 · Cited by 12
HDL and coronary heart disease—novel insights
Landmesser, U. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.128 · Cited by 12
Targeting Lipoprotein (a): an Evolving Therapeutic Landscape
Man, L. C., Kelly, E. M., & Duffy, D. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0502-0 · Cited by 10
Blood Lipids and Type 2 Diabetes Risk: Can Genetics Help Untangle the Web?
Swerdlow, D. I., & Sattar, N. A. (2015) · Diabetes · doi:10.2337/db15-0458 · Cited by 8
Lipid parameters in patients with acute coronary syndromes versus stable coronary artery disease
Vonbank, A., Saely, C. H., Rein, P., & Drexel, H. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12513 · Cited by 9
High prevalence of raised lipoprotein(a) in patients with refractory angina
Khan, T. Z., Rhodes, S., Pottle, A., BANYA, W. A. S., Smith, R. D., Kabir, T., Ilsley, C. D. J., Pennell, D. J., & Barbir, M. (2015) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2015.28 · Cited by 9
“drug does not reduce major adverse cardiac events and causes a higher incidence of serious non-fatal side effects.(15) The proprotein convertase subtilisin kexin type 9 (PCSK9) monoclonal antibody, Evolocumab (AMG”
BackgroundRecent developments in modulating atherogenic lipoproteins
White, C. R., Goldberg, D., & Anantharamaiah, G. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000216 · Cited by 11
Toplak, H., Ludvik, B. H., Lechleitner, M., Dieplinger, H., Föger, B., Paulweber, B., Weber, T., Watschinger, B., Horn, S., Wascher, T. C., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0993-x · Cited by 15
Park, S. J., Yeum, K., Choi, B. H., Kim, Y. S., & Joo, N. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0459-z · Cited by 8
Pang, D., Nong, Z., Sutherland, B. G., Sawyez, C. G., Robson, D. L., Toma, J., Pickering, J. G., & Borradaile, N. M. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.233 · Cited by 9
“Negative outcomes of recent large clinical trials (Boden et al. 2011; Haynes et al. 2013; Landray et al. 2014) have challenged the clinical utility of high-dose niacin in combination with statins for long-term treatment of dyslipidemia in patients with characteristics of metabolic syndrome.”
BackgroundEffects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a)
Vavlukis, M., Mladenovska, K., Daka, A., Dimovski, A. J., Domazetovska, S., Kuzmanovska, S., & Kedev, S. A. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016652415 · Cited by 9
Combined Dyslipidemia in Children and Adolescents
Kavey, R.-E. W. (2016) · Cited by 9
Maser, R. E., Lenhard, M. J., Pohlig, R. T., & Balagopal, P. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.12.002 · Cited by 8
“Nevertheless, clinical trials to test the hypothesis that raising HDL-C levels will result in reduction of cardiovascular events have not been successful [29,30].”
BackgroundXu, D., Hu, J., Wu, Q., Du, Z., Xue, Y., Zhang, X., Li, Y., Chen, Y., Chen, X., Zhang, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18329 · Cited by 9
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort
Probstfield, J. L., Boden, W. E., Anderson, T. J., Branch, K. R., Kashyap, M. L., Fleg, J. L., Desvigne-Nickens, P. M., McBride, R., & McGovern, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.07.007 · Cited by 9
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00037-x · Cited by 23
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
Parhofer, K. G., Chapman, M. J., & Nordestgaard, B. G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa116 · Cited by 12
“Niacin In a similar manner to fibrates, niacin therapy has been shown to translate into benefit when used without statins but did not show benefit in combination with statins.(40,41,55) Niacin is therefore no longer available in most countries and should not be used to treat patients with hypertriglyceridaemia or comb…”
ResultGenetics of Coronary Atherosclerosis
Aragam, K. G., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00003-0 · Cited by 9
Liu, R., & Cheng, W. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14754 · Cited by 7
“Over time, the accumulation of these changes may trigger a chronic inflammatory state that may hinder the cardioprotective ability of HDL. 16,25 Menopausal hormonal changes could lead to the accumulation of CVD risk factors.”
BackgroundKhan, M. I., Zahir, R. S., Dominguez, A. C., & Romeo, F. J. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101543 · Cited by 15
Birză, M. R., Negru, A. G., Frent, S., Florescu, A.-R., Popa, A. M., Manzur, A. R., Lascu, A., & Mihaicuta, S. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061922 · Cited by 14
“An investigation of night-to-night variability in OSA severity found that nights with the highest severity had an increased risk of having AF during the same day [77].”
Elevated high-density lipoprotein triglycerides increase atherosclerotic risk
Liu, W., Chen, S., Yang, C., Lei, F., Huang, X., Zhang, X., Sun, T., Lin, L., Wang, C., Cao, Y., et al. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100791 · Cited by 12
“Although epidemiological studies generally demonstrate an inverse relationship between HDL cholesterol (HDL-C) levels and ASCVD risk, clinical trials aimed at increasing HDL-C levels have not consistently shown a reduction in ASCVD events (5, 6, 8, 10 – 13).”
Franczyk, B., Młynarska, E., Rysz-Górzyńska, M., Gluba-Brzózka, A., Rysz, J., Sheth, S., Surma, S., Banach, M., & Toth, P. P. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101068 · Cited by 10
“…Low HDL-C and High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2 – Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) — showed substantial increases in HDL-C, but this did not translate into significant CV risk reduction [145,146].”
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 97
ω-3 carboxylic acids for hypertriglyceridemia
Roth, E. M. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.991307 · Cited by 8
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
Pareek, M., Mason, R. P., & Bhatt, D. L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1954158 · Cited by 8
Ye, H., Wang, G., Wang, X., Wang, X., Ni, W., Chen, L., Zhu, Y., Zhao, L., Xiong, Z., Wang, Y., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116444 · Cited by 9
All we need to know about lipoprotein(a)
Bess, C., Mehta, A., & Joshi, P. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.05.007 · Cited by 17
Anderson, T. J. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.03.019 · Cited by 8
Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention
Page, M. M., & Watts, G. F. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1035709 · Cited by 9
“The recent HPS2-THRIVE placebocontrolled study of niacin added to a statin with or without ezetimibe was prematurely terminated due to an excess of myopathy in patients receiving niacin, particularly Chinese patients, and did not prove a benefit in terms of cardiovascular outcomes [20].”
BackgroundHDL metrics, let’s call the number thing off?
Sposito, A. C. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.044 · Cited by 8
Should an LDL-Cholesterol Target–Based Approach Be Readopted?
White, C. M., Weeda, E. R., & Nguyen, E. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017722009 · Cited by 7
“The number and size of trials quantifying the benefits of higher versus lower intensive statin therapy and our familiarity with this class of drugs is much better than the alternative adjunctive agents.(9-17) As such, pushing to the maximum statin dose or the maximum tolerated dose before moving to adjunctive therapy…”
BackgroundMethodInfluentialde Expertos, G. D. T. D. D. A. D. L. S. E. D. A. Y. G. E. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.12.001 · Cited by 13
Inhibition of hepatic apolipoprotein A-I gene expression by histamine
Haas, M. J., Plazarte, M., Chamseddin, A., Onstead‐Haas, L., Wong, N. C. W., Plazarte, G., & Mooradian, A. D. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.01.035 · Cited by 8
Wadowski, P. P., Lee, S., Kopp, C. W., Koppensteiner, R., Panzer, S., & Gremmel, T. (2018) · Angiology · doi:10.1177/0003319718760074 · Cited by 10
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.